The Condor Team

Clinical trials are not static financial environments. They are extremely change-intensive financial environments. Protocols get amended. Sites open and close. Patient enrollment accelerates or stalls. CROs revise invoices mid-study. Every one of those changes has a financial consequence, and every one of those consequences has to be tracked, reconciled, and reported — accurately, on a deadline, by a team that is almost never large enough.

For a long time, a skilled finance professional with a well-built spreadsheet could absorb that complexity. Not anymore. 

Here's what the work actually looks like today. For each active trial, a finance team has to gather CRO reports, pull individual site contracts, compare patient activity data from the clinical team, and manually reconcile everything into a single spreadsheet — ticking and tying across multiple workbooks to arrive at an accrual number they can stand behind. One study, done thoroughly, consumes a full day of multiple people's time. For a company running three to five concurrent trials, quarter-end close can eat nearly a week of the finance team's calendar. Every quarter.

And that's before accounting for errors. Not because the people doing this work are careless — they are not. But because every manual reconciliation is a point of failure. A VLOOKUP pulling from the wrong workbook. A formula that didn't carry through. A CRO invoice that billed multiple patient visits at the wrong rate. These errors exist. They compound. And in many cases, nobody catches them.

Some teams try to solve this by outsourcing the manual work to a software vendor's services team. The logic is understandable, but the risk doesn't transfer with the work. Your name is still on the accruals. Your auditors still come to you, not the vendor, when a number needs to be defended. And you've inserted a human layer between your finance team and the data, which means longer cycles to get answers, to close the books, and to react when a trial's burn rate shifts. The bar for modern R&D finance isn't "faster than a spreadsheet." It's real-time visibility your team controls. 

The problem is structural. Clinical trials have gotten too complex, too fast-moving, and too financially consequential for spreadsheets. 

There is a better way. At Compass Therapeutics — a lean biotech managing three to five concurrent Phase 1 and Phase 2/3 trials with a two-person finance team — the old process consumed a full day per study, every close. After moving to Condor, that dropped to half a day per study, including reviewer time. Across their active portfolio, they recovered nearly a week of close time every quarter. They caught billing errors that the spreadsheet process never surfaced. They replaced site-level averaging with contract-accurate estimates for every individual site. And they absorbed additional trial volume as their portfolio grew, without adding headcount.

That's what financial infrastructure is supposed to do; it's supposed to scale with the science.

Condor's AI-powered platform automatically connects and unifies clinical, operational, and financial data from the systems and vendors R&D teams already use, eliminating the manual reconciliation layer entirely. Every accrual reflects the actual contracted rate. Every variance is visible. Every number comes with the audit trail that regulators and auditors expect. The manual work doesn't get reassigned. It gets replaced.

Spreadsheets had a good run. But their time has come and gone.

Introduction: Why Clinical Trial Accrual Automation Is No Longer Optional

For biopharma finance teams, clinical trial accruals take a lot of time. They are also prone to errors during the R&D close. Analysts spend days chasing CRO invoices. They manually reconcile spreadsheets and build accrual estimates. Those estimates are outdated the moment they are finished. At the end of the month, the team is exhausted and the numbers are still wrong.

The good news is this does not have to be the norm. Automating clinical trial accruals is now within reach for biopharma companies of all sizes — and the results are measurable. Teams that have made the shift report up to a 75% efficiency gain, a 60% faster close cycle, and forecast accuracy that exceeds 90%.

This guide explains what clinical trial accrual automation means. It explains why this challenge is especially difficult in biopharma R&D. It also shows how to approach it step by step. It explains what to look for in a purpose-built solution.

What Are Clinical Trial Accruals?

A clinical trial accrual is the process of recording R&D expenses in the correct accounting period. It applies even if invoices arrive later. Under GAAP and IFRS, biopharma companies must record costs as providers perform the services, not when providers bill them.

In practice, this means estimating how much work a CRO, clinical site, or other vendor finished by each period end. This applies even if no invoice has arrived. The accrual bridges the gap between operational progress and the general ledger.

Clinical trial accruals typically cover:

• CRO pass-through and service fees based on milestone completion and percent-complete estimates
• Investigator fees and site costs tied to patient enrollment and visit activity
• Central lab, imaging, and ancillary vendor costs based on sample volumes and service delivery
• Change orders and protocol amendments that alter original contract values
• Foreign exchange adjustments for multi-currency global studies

Each of these streams requires different data sources, different calculation logic, and different sign-off workflows. Across a portfolio of five or ten active trials, the complexity compounds quickly.

Why Manual Accrual Processes Break Down in Biopharma

Most biopharma finance teams still use ERP systems (SAP, Oracle, NetSuite), Excel files, and email to manage clinical accruals. This approach creates four structural problems that no amount of spreadsheet optimization can solve.

1. Lack of Real-Time Visibility

Accruals calculated from delayed CRO invoices or month-end confirmations are always looking backward. By the time estimates are final, study activity may have shifted. Enrollment may speed up, a site may drop out, or a protocol amendment may change scope. The accrual goes stale before you post it.

2. High Dependency on Manual Processes

Building an accrual model in Excel requires analysts to pull data from many systems. These can include EDC platforms, IRT systems, procurement tools, and contract management systems.

Analysts then copy the data into a workbook, apply formulas, and reconcile results with prior periods. Each handoff introduces the risk of error. Each formula cell is a potential failure point that auditors will want explained.

3. Disconnected Systems and Siloed Data

No single system connects operational trial progress to financial impact. Clinical operations teams track enrollment in one platform; finance tracks budget vs. actuals in another. When a change order is approved, the accrual model does not update automatically.

When a site is activated, the accrual model does not update automatically. Finance hears about it at month-end — if they hear about it at all.

4. Forecast Inaccuracy and Budget Overruns

Static accrual models assume the world stays constant between updates. In clinical development, it never does. Without dynamic, scenario-aware models, finance teams can't accurately project trial spend — and programs run over budget without warning.

"Condor is like night & day from our previous models." — Trishula Therapeutics

The Anatomy of a Modern Clinical Trial Accrual Process

Before you can automate the process, it helps to understand what a well-designed accrual workflow actually looks like. The architecture has three distinct layers.

Layer 1: Data Ingestion

The inputs to any clinical accrual include:

• Contract data — CRO agreements, CTAs, site contracts, and all associated change orders
• Operational assumptions — enrollment timelines, site activation status, percent-complete by service line, and visit completion rates
• Live operational data — EDC data (grant activity), IRT data (site-level enrollment), ERP transaction data, and procurement system records

In a manual process, analysts gather this data by hand. In an automated process, integrations pull this data continuously and map it to the right contract line items.

Layer 2: Calculation and Processing

With the right data, the system uses calculation logic to create accrual estimates for every vendor and service line. This includes:

• Percent-complete calculations for CRO services
• Investigator fee accruals based on visit activity
• Foreign exchange gain/loss calculations for global studies
• Amendment-in-progress reconciliations when change orders are pending

Layer 3: Outputs and Workflow

The outputs of the accrual process feed directly into the financial close. Specifically, the system produces:

• Journal entries ready for ERP posting
• Vendor reconciliation packages for CRO review and sign-off
• SOX/SOC-compliant audit logs and supporting documentation
• Dashboards showing accrual status, budget vs. actual, and trial-level spend

This is also where the guided workflow lives. It includes checklists, role-based approvals, and audit trails. These features make the close defensible to Big 4 auditors.‍‍

How to Automate Clinical Trial Accruals: A Step-by-Step Approach

Step 1: Centralize Your Contract Data

The foundation of any accrual automation effort is a unified, structured repository of all your clinical contracts and amendments. This means contract value by service line, milestones, budget categories, and all approved change orders.

Without this foundation, automation is impossible — you can't calculate percent-complete against a contract you haven't structured. Start by extracting and standardizing your CRO agreements, CTAs, and ancillary vendor contracts.

Step 2: Map Operational Data to Financial Categories

Next, create a reliable link between your study work and the records in the general ledger. This requires SMART mapping logic. It translates key milestones, like a patient visit, a lab sample, or site activation. It maps them to matching contract line items and budget categories.

This mapping is where purpose-built clinical finance software creates the most value. Generic ERP systems and accrual tools were not built for the clinical R&D data model.

They need major custom setup, or manual workarounds, to meet these needs.

Step 3: Integrate Your Data Sources

Once your contracts are structured and your mapping logic is in place, you need live data flowing into your accrual models. Integration points typically include:

• EDC platforms (Medidata, Veeva Vault, etc.) for grant and visit data
• IRT systems for site-level enrollment and randomization
• ERP and procurement systems for purchase orders and invoice status
• Contract management systems for approved change orders and amendment status

Automated data ingestion eliminates the manual copy-paste that accounts for a significant portion of close cycle time — and the majority of accrual errors.

Step 4: Automate Calculations and Reconciliations

With structured data flowing in, the system can calculate accruals programmatically. Automated calculations should cover:

• CRO service accruals by percent-complete methodology
• Pass-through cost accruals based on operational data
• Investigator fee calculations by site and patient activity
• Gain/loss calculations for foreign-denominated contracts
• Intelligent reconciliation against prior-period estimates and invoices received

Automation here doesn't mean black-box algorithms. It means repeatable, auditable logic that finance teams can explain to auditors and sign off on confidently.

Step 5: Implement Guided Close Workflows

Automation handles the calculation. Workflow automation handles the coordination. A purpose-built clinical finance system should include:

• A financial close checklist with task assignments and status tracking
• Role-based approvals for accrual review and sign-off
• Integration with accounting systems for journal entry posting
• Audit logs that capture every change, assumption update, and approval

This is where SOX compliance gets built in rather than bolted on. Teams working toward IPO readiness or operating under external audit scrutiny will find that structured workflows reduce the risk of audit findings tied to clinical R&D accruals.

"This [financial close] would never have been possible without Condor." — Intra-Cellular Therapies

Step 6: Build Dynamic Forecasting on Top of Actuals

The final step — and the one that transforms accruals from a compliance function into a strategic tool — is connecting accrual actuals to a forward-looking forecast. When your accrual data is clean, structured, and current, you can build scenario models that project trial spend under different enrollment, amendment, and timeline assumptions.

This closes the loop between the close process and FP&A, giving CFOs and VPs of Finance the real-time visibility they need to manage R&D budgets proactively.

Key Capabilities to Look for in a Clinical Trial Accrual Automation Platform

Not all clinical finance tools are built the same. When evaluating solutions, look for these capabilities:

Purpose-built clinical data model

Generic ERP add-ons and industry-agnostic accrual tools (like Gappify or BlackLine) were not designed with biopharma R&D workflows in mind. A purpose-built platform should natively understand CRO contracts, CTAs, investigator fees, and protocol amendments — without requiring custom configuration to model these structures.

Automated data ingestion

Look for native integrations with EDC platforms, IRT systems, ERP systems, and procurement tools. Manual data imports are a bottleneck and a source of error.

SMART mapping and intelligent reconciliation

The system should automatically map operational data to contract line items, flag variances, and surface amendment-in-progress situations that require reconciliation before the close.

SOX-compliant audit trail

Every calculation, assumption change, and approval should be logged with user, timestamp, and rationale. This is non-negotiable for public companies and Series C+ stage companies preparing for audit.

Unified view for Accounting, FP&A, and Clinical‍

‍The best systems give each function a role-specific dashboard built on the same underlying data model — so there's one version of the truth, not three.

Scenario-based forecasting

The platform should allow finance teams to run "what if" models based on enrollment changes, protocol amendments, or timeline shifts — with the accrual layer feeding directly into the forecast.‍

The Business Case for Clinical Trial Accrual Automation

The ROI on clinical accrual automation compounds quickly. Organizations that have implemented purpose-built automation report:

• 75% efficiency gain on the accrual process itself
• 60% faster financial close cycle
• 90%+ forecast accuracy versus prior-period actuals
• 20% savings per change order through improved reconciliation
• $200K–$10M in vendor budget savings per trial, on average

Beyond the numbers, there is a scaling benefit that spreadsheet-based processes simply cannot provide. One company scaled from 2 active trials to 10 in 120 days — without adding headcount — because their accrual process no longer required a dedicated analyst per study. Another team unlocked over $5M in clinical program savings in a single program through better vendor reconciliation and change order management.

For finance leaders, the business case is straightforward: manual accruals are a constraint on how fast the company can grow. Automation removes that constraint.

Common Objections — and How to Address Them

"We already have an ERP."

ERPs manage transactions. They were not built to calculate clinical trial accruals based on percent-complete methodologies and operational trial data. Most companies using SAP or Oracle for clinical accruals are doing the actual calculation in Excel and posting the result to the ERP. The automation opportunity is in the calculation layer, not the GL.

"Our process works fine for now."

Manual processes work until they don't.

Inflection points often come sooner than teams expect. A new CFO might join. An IPO process might start.

A Series C audit might begin. A pipeline might expand. Building automation early is far less disruptive than adding it under pressure during a close or audit.

"We don't have the IT resources for implementation."

Purpose-built clinical finance platforms support fast implementations with minimal IT burden. The heavy lifting is in the clinical data model and integration layer. It comes pre-built, not from custom development.

Conclusion: From Reactive Close to Proactive Control

Automating clinical trial accruals is not just an efficiency play. It is the foundation for transforming clinical finance from a reactive, backward-looking function into a proactive one.

Finance teams gain real-time visibility into trial spend. They also get accurate forecasts. They can scale as the pipeline grows.

Centralize your contract data. Link your key operational data sources. Move calculations out of spreadsheets and into a purpose-built system. The result is a faster close, cleaner audits, and a finance team that keeps up with complex biopharma R&D.

Condor is the Financial Cloud for Pharma R&D — purpose-built to automate clinical trial accruals, forecasting, budgeting, and benchmarking. To learn how leading biopharma finance teams are automating their R&D accruals with Condor, request a demo at condorsoftware.com.

The Hidden Cost of Manual Accruals in Clinical Finance

Clinical trials are among the most complex financial undertakings in any industry. Each study involves many vendors, hundreds of sites, and thousands of patient visits. A finance team must report on it all with speed and accuracy.

For many biopharma companies, that reporting still relies on spreadsheets, late invoices, and manual estimates. People often pull these together in the week before close.

Accruals that are weeks behind reality. Forecasts that don't reflect actual enrollment. And accounting teams spending more time reconciling data than driving insight.

Clinical trial accruals software solves this exact problem. It automates trial expense calculations, reconciliations, and reporting. Finance teams can close faster, forecast better, and stay audit-ready at all times.

"I can't imagine handling closes for all our new studies without Condor. It has changed how we work. It saves us time and cuts down on errors."

— Associate Director, Finance at a public biotech targeting neurological disorders

What Is Clinical Trial Accruals Software?

Clinical trial accruals software is financial technology built for trials. It automates the estimating and recording of clinical trial expenses for an accounting period. It does this even if invoices arrive later.

In standard accounting, accruals ensure that you recognize costs when you incur them, not when you bill them. In clinical research, this is especially challenging. Trial work continues across CROs, sites, and third-party vendors. Each has different billing schedules, change order histories, and data formats.

Best-in-class clinical trial accruals software links to your operational data. It connects to EDC, IRT, CMS, and ERP systems. It uses activity data like patient enrollment and site completions.

It also uses service period status. It then calculates accruals dynamically. It does not rely on lagging invoices or manual estimates.

The Four Core Problems It Solves

1. Lack of real-time visibility
   Accruals built on delayed invoices or manual confirmations produce financials that are already outdated by the time they're presented.
2. High dependency on manual processes
   Spreadsheet-based estimates increase human error, drain finance resources, and create audit exposure when assumptions can't be traced.
3. Disconnected, siloed systems
   Without a unified system, change orders, protocol amendments, and enrollment shifts aren't systematically reflected in accruals or forecasts.
4. Forecast inaccuracy and budget overruns
   Static models can’t capture real changes in study activity. They also can’t run dynamic “what if” scenarios when they matter most.

Why Biopharma Finance Teams Are Prioritizing This Now

The economics of drug development have never been under more scrutiny. With R&D budgets shrinking, clinical finance leaders must do more with less.Regulatory demands are increasing. Clinical trials are becoming more complex. They must also keep the accuracy that SOX rules and Big 4 audits require.

Key outcomes Condor customers achieve:

• 70% faster financial close cycle with automated accruals
• 90%+ forecast accuracy
• $5M+ saved in a single clinical program

Manual accrual processes that once served a portfolio of two or three trials become unsustainable at ten or twenty. Teams can grow without adding headcount when they automate the accrual engine under their close process.

What to Look for in Clinical Trial Accruals Software

Not all solutions are created equal. When evaluating clinical trial accruals software, biopharma finance teams should look for the following capabilities:

1. Automated Accruals Engine
   Calculates trial-level accruals using real operational data , not just invoices with built-in SOX controls and audit trails.
2. Clinical Data Ingestion
   Connects to EDC, IRT, ERP, procurement, and contract management systems to create a unified financial view of each trial.
3. Forecasting & Scenario Planning
   Dynamic trial-level models with multi-scenario "what if" analysis. Finance teams can react fast to enrollment shifts or protocol changes.
4. Vendor & Change Order Management
   Tracks contract changes and vendor budgets. Compares actuals to forecasts. Flags overruns early, before they become write-offs.
5. Role-Based Reporting
   Stakeholder-specific dashboards for Clinical, FP&A, and Accounting — all drawing from the same underlying data model.
6. Audit Readiness & SOX Compliance
   End-to-end audit logs, role-based permissions, financial close checklists, and controls designed with Big 4 auditors in mind.

How Condor Automates Clinical Trial Accruals

Condor is the Financial Cloud for R&D — purpose-built for biopharma, by biopharma. Our platform automates clinical trial accruals, forecasting, budgeting, and benchmarking in a single connected system that spans Accounting, FP&A, and Clinical Operations.

Unlike generic ERP modules or spreadsheet add-ons, Condor's accruals engine matches how clinical trials work. It supports contracts with CROs and CTAs. It tracks enrollment milestones, site activity, service periods, and investigator fees. It calculates each item with the precision and traceability that audit teams require.

The result is a 75% efficiency gain in accrual workflows and a 70% faster close cycle. Forecast accuracy consistently exceeds 90%.

This happens without adding finance headcount as trial portfolios scale.

"Condor saved us over $5M on one program. We also went from 2 trials to 10, without adding resources."

— Director, Accounting at a public biotech with Phase 2 & 3 mRNA therapy trials

‍

The Bottom Line

Clinical trial accruals are too consequential —and too complex — to be managed in spreadsheets. For biopharma finance teams that manage many trials, closing the books faster matters.

Audit reviews are also stricter. Purpose-built clinical trial accruals software is essential. It's the infrastructure that makes everything else possible.

If your team is still closing on estimates and chasing CRO invoices, there's a better way. Condor automates accruals, gives real-time visibility, and keeps an audit trail for every number. Your team can focus on decisions, not reconciliations.

See Condor's Accruals Engine in Action

Request a personalized demo and learn how Condor can transform your clinical trial accruals process — from reactive to proactive.

Visit condorsoftware.com to request a demo.

Biotech companies rely on outsourced research and development (R&D) to speed innovation, access specialized expertise, and control costs. However, accounting for these outsourced activities, particularly clinical trial accruals, presents challenges that demand financial oversight and strategic planning.

Emerging life sciences companies often engage multiple Contract Research Organizations (CROs) for clinical trials, each with distinct contracts, payment structures, and invoicing schedules. As trials progress, finance teams must track service milestones, estimate unbilled services, and ensure accurate financial reporting. Getting this right is essential for compliance with U.S. Generally Accepted Accounting Principles (US GAAP) and for making sound business decisions.

Clinical Trial Accruals Must Be Accurate to Ensure Financial Integrity

Clinical trial accruals are one of the most complex areas of biotech finance. Companies must record expenses as they are incurred, even before invoices arrive. This means estimating the cost of services delivered but not yet billed—a task complicated by differences between invoicing terms and actual service delivery.

For biotech firms running multiple trials, the challenge is even greater. They must juggle various CROs, manage multiple agreements, and maintain precise records of trial progress. Errors in these accruals can lead to financial misstatements, eroding investor confidence and, in some cases, requiring restatements.

Accurate Accruals Require the Right Methods, Sound Assumptions, and Reliable Data

Accurate clinical trial accruals depend on a few essential elements:

1. Choosing the Right Methodology

Finance teams use different methods depending on the complexity of the trial and the contract structure. In particular, contracts with CROs often fall into three categories:

• Direct Service Fees – Costs tied to specific units of work or milestones.
• Investigator Fees – Payments to trial sites and patient costs.
• Pass-Through Costs – Expenses incurred by the CRO on behalf of the biotech company.

For small Phase 1 trials, milestone-based or timeline amortization methods often suffice. For larger, later-phase trials, companies may need more detailed tracking methods based on patient enrollments, site activations, and study timelines.

2. Establishing Sound Assumptions

Since estimates are forward-looking, finance teams must base them on solid assumptions, such as:

• Expected patient enrollment and site activations.
• Trial duration and expected protocol changes.
• Cost per patient and site.

Close collaboration between finance and clinical operations is essential to refining these estimates.

3. Ensuring Data Accuracy

Reliable accruals require timely and comprehensive data, including:

• Patient visit records and trial procedures.
• Milestone progress reports.
• Contract amendments and invoices received.

Maintaining an integrated data management system that centralizes this information improves financial accuracy and efficiency.

Recognizing these key factors is crucial, but companies must also take actionable steps to improve financial reporting and compliance. Implementing best practices can help finance teams navigate these complexities and create a structured approach to clinical trial accruals.

Strengthening Financial Oversight in Outsourced R&D Requires a Structured Approach

To navigate the complexities of outsourced R&D, biotech companies can use this checklist to ensure financial accuracy and compliance:

✅ Establish Clear Accounting Policies

• Do we have standardized accounting policies specific to outsourced R&D activities?
• Are the methodologies for estimating and recording clinical trial accruals clearly defined?
• Are similar outsourced R&D activities accounted for consistently?

✅ Align Internally Before Engaging Vendors

• Have finance, clinical operations, and procurement teams aligned on key financial reporting needs?
• Have internal teams set clear expectations on data collection and reporting deadlines?
• Are roles and responsibilities clearly defined for managing vendor financial data?

✅ Review Key Contract Terms

• Do we fully understand the payment structures and milestone agreements in CRO contracts?
• Are budget assumptions clearly outlined and aligned with financial forecasts?
• Have we reviewed contracts to ensure all financial obligations are captured accurately?

✅ Foster Cross-Functional Collaboration

• Do finance and operational teams communicate regularly to discuss trial progress and financial projections?
• Is there a structured process for sharing real-time updates on cost changes, site activations, or enrollment fluctuations?
• Are clinical and finance teams aligned on trial timelines and budget adjustments?

✅ Regularly Review Assumptions

• Are we periodically reassessing key financial assumptions?
• Do our accrual estimates reflect the latest updates on patient enrollment, site activations, and costs?
• Are there processes in place to adjust financial projections based on evolving trial conditions?

✅ Implement Strong Monitoring and Controls

• Are we reconciling invoices against services provided and accrual estimates regularly?
• Do we have tracking mechanisms to verify the accuracy of financial reporting?
• Are we maintaining a system to document all financial changes and contract modifications?

By following this checklist, companies can ensure that they have a structured approach to managing outsourced R&D accruals while maintaining compliance with US GAAP and fostering financial transparency.

Financial Discipline in Outsourced R&D Drives Long-Term Biotech Success

Outsourced R&D is critical to biotech innovation, but it brings financial challenges. By implementing strong accounting policies, refining assumptions, improving data accuracy, and fostering cross-functional collaboration, companies can navigate these complexities and maintain compliance with US GAAP.

In the biotech industry, financial transparency is as important as scientific progress. A disciplined approach to managing outsourced R&D accruals ensures financial health, investor confidence, and long-term success.

‍

Clinical trials are among the most complex financial endeavors in biotech, requiring careful financial planning, tracking, and reconciliation. Ensuring accurate financial reporting and vendor accountability means answering three key questions: What do we expect to happen? What has actually happened? And what is driving the variance between expectations and reality?

The Challenge of Forecasting Clinical Trial Costs

Unlike other industries where cost forecasting follows predictable patterns, clinical trials introduce many unpredictable variables. Enrollment rates, protocol amendments, and site-specific costs can make standard financial tools ineffective. Forecasting must be dynamic, aligning cost distributions with actual clinical drivers rather than relying on broad assumptions.

Accrual accounting—determining costs incurred but not yet paid—is another essential component. Many companies still rely on spreadsheets to manage this process, but doing so often leads to inefficiencies. When data is delayed or inaccurate, finance teams must choose between speed and accuracy, a trade-off that can complicate compliance and financial reporting.

The Pitfalls of Straight-Lining Costs

One common but problematic approach is straight-lining costs—spreading expenses evenly over time. While this method may seem simple and efficient, it often leads to major financial and compliance issues. Inaccurate accrual estimates can trigger audit misstatements, requiring time-consuming adjustments and increasing the risk of financial restatements.

A better alternative is to use activity-based accruals and multi-source triangulation—leveraging multiple data sources to validate costs. This approach provides a more accurate picture of clinical trial expenses and enhances financial reporting. While implementing an automated accrual system requires upfront effort, the long-term benefits include faster close times, improved audit readiness, and reduced financial risk.

Case Study: Ventyx’s Transition to Automated Accruals

Ventyx, a leading biopharmaceutical company, faced significant inefficiencies in their R&D accrual process. Heavy reliance on CRO reporting and manual processes led to long close cycles, frequent audit adjustments, and budgeting challenges. Managing multiple Phase 1 and Phase 2 trials further complicated financial forecasting.

By adopting an automated accrual platform, Ventyx reduced their monthly close process by 78%, completing it in under a week. The impact was significant:

• Efficiency: Faster and more reliable accrual processing.
• Accuracy: Fewer post-close adjustments and better compliance.
• Collaboration: Improved communication across finance, FP&A, and clinical operations.
• Vendor Management: Enhanced visibility and stronger contract negotiation capabilities.
• Audit Readiness: Strengthened SOX compliance and reduced audit-related inquiries.

As Roy Gonzales, Senior Vice President of Finance at Ventyx, stated:

"Previously, our close process spanned between 3 to 4 weeks and heavily relied on our CRO. Our new system enabled us to streamline our monthly close process, cutting it down to under a week."

Ventyx’s experience underscores a crucial point: organizations don’t have to choose between speed and accuracy. By leveraging automation, they can achieve both.

The Role of Automation in Clinical Trial Financial Management

As clinical trial portfolios grow, managing financial reporting manually becomes unsustainable. Automation bridges the gap between finance, accounting, and clinical operations by:

• Integrating vendor contracts, change orders, and out-of-scope costs in real time.
• Ensuring forecasts and actuals remain aligned.
• Providing structured data that enhances transparency and decision-making.

Organizations that invest in automation transition from reactive financial management to proactive strategic oversight. By removing inefficiencies and enhancing data accuracy, finance teams can support broader business objectives more effectively.

Final Thoughts

Clinical trial financial management requires a delicate balance between efficiency and accuracy. While straight-lining costs may seem like an easy solution, it often creates more problems in the long run. Investing in automation, adopting multi-source triangulation, and aligning finance with clinical operations can ensure long-term financial stability.

The takeaway is clear: accurate, fast, and compliant accruals are not mutually exclusive. By making the right investments, biotech companies can streamline operations and gain greater financial control.

‍